目的 研究汉化版国际帕金森和运动障碍协会(MDS)-统一帕金森病评定量表(UPDRS)的信度和效度，及其与传统UPDRS的比较分析。 方法 2016年5月至2018年12月，分别对225例帕金森病患者进行两个量表的测评，评价MDS-UPDRS的信度和效度，进一步对两个量表作相关分析。 结果 MDS-UPDRS整体Cronbach α系数为0.734。秩相关系数为0.905。因子分析KMO统计量为0.728。Pearson相关分析，两个量表的公因子相关系数为0.969，两个量表的总分相关系数为0.972。且MDS-UPDRS相比UPDRS，增加了许多非运动症状，调整了度量标准从而提高了对疾病早期评估的精确度，增加了大量指导语从而规范测评。 结论 汉化版MDS-UPDRS具有较好的信度和效度，与传统UPDRS相关性较高，且比UPDRS更适合用于中国帕金森病患者进行临床评定。
Objective To evaluate the reliability and validity of Chinese version of International Parkinson and Movement Disorder Society (MDS)-Unified Parkinson's Disease Rating Scale (UPDRS), and then do comparative analysis with original UPDRS. Methods From May, 2016 to December, 2018, 225 patients with Parkinson's disease were respectively evaluated by MDS-UPDRS and UPDRS, and then the reliability and validity of MDS-UPDRS were evaluated. Correlation between two scales was analyzed. Results The Cronbach's coefficient of the total MDS-UPDRS was 0.734. Rank correlation's coefficient was 0.905. For factor analysis, KMO was 0.728. Pearson's correlation analysis showed that the correlation's coefficient of the common factor of the two scales was 0.969, while the correlation's coefficient of the total score of the two scales was 0.972. Compared with UPDRS, MDS-UPDRS added a number of non-motor symptoms, which adjusted the standard of measurement and increased the accuracy degree of evaluation at early stage of disease. Besides, MDS-UPDRS added a lot of instructions to evaluate the standards to make the evaluation normatively. Conclusion Chinese version of MDS-UPDRS has high reliability and validity, and highly correlate with the original UPDRS. It is more suitable for Chinese patients with Parkinson's disease in clinical evaluation than UPDRS.
1 Martinez-MartinP, Rodriguez-BlazquezC, Alvarez-SanchezM, et al. Expanded and independent validation of the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) [J]. J Neurol, 2013, 260(1): 228-236.
2 AntoniniA, AbbruzzeseG, Ferini-StrambiL, et al. Validation of the Italian version of the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale [J]. Neurol Sci, 2013, 34(5): 683-687.
3 KashiharaK, KondoT, MizunoY, et al. Official Japanese Version of the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale: validation against the original English version [J]. Mov Disord Clin Pract, 2014, 1(3): 200-212.
4 AkbostanciM C, BayramE, YilmazV, et al. Turkish Standardization of Movement Disorders Society Unified Parkinson's Disease Rating Scale and Unified Dyskinesia Rating Scale [J]. Mov Disord Clin Pract, 2017, 5(1): 54-59.
5 ZitserJ, PeretzC, Ber DavidA, et al. Validation of the Hebrew version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale [J]. Parkinsonism Relat Disord, 2017, 45: 7-12.
6 中华医学会神经病学分会帕金森病及运动障碍学组,中国医师协会神经内科医师分会帕金森病及运动障碍专业. 中国帕金森病的诊断标准(2016版)[J]. 中华神经科杂志, 2016, 49(4): 268-271.
7 GoetzC G, PoeweW, RascolO, et al. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations [J]. Mov Disord, 2003, 18(7): 738-750.
8 GoetzC G, TilleyB C, ShaftmanS R, et al. Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results [J]. Mov Disord, 2008, 23(15): 2129-2170.
9 LangA E, EberlyS, GoetzC G, et al. Movement disorder society unified Parkinson disease rating scale experiences in daily living: longitudinal changes and correlation with other assessments [J]. Mov Disord, 2013, 28(14): 1980-1986.
10 Rodriguez-BlazquezC, Rojo-AbuinJ M, Alvarez-SanchezM, et al. The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson's disease [J]. Parkinsonism Relat Disord, 2013, 19(10): 889-893.
11 RacitiL, NicolettiA, MostileG, et al. Accuracy of MDS-UPDRS section IV for detecting motor fluctuations in Parkinson's disease [J]. Neurol Sci, 2019, 40(6): 1271-1273.
12 Martinez-MartinP, Rodriguez-BlazguezC, AlvarezMario, et al. Parkinson's disease severity levels and MDS-Unified Parkinson's Disease Rating Scale [J]. Parkinsonism Relat Disord, 2015, 21(1): 50-54.
13 RegnaultA, BoroojerdiB, MeunierJ, et al. Does the MDS-UPDRS provide the precision to assess progression in early Parkinson's disease? Learnings from the Parkinson's progression marker initiative cohort [J]. J Neurol, 2019, 266(8): 1927-1936.
